Selected Grants
: A Phase 3, Single-Arm, Multi-Dose, Pharmacokinetic Comparability Trial between TAK-881 and HYQVIA in Adults with Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Clinical TrialPrincipal Investigator · Awarded by Takeda Development Center Americas, Inc · 2025 - 2028Inflammatory Neuropathy Consortium data Base (INCBase): A prospective international CIDP registry
ResearchPrincipal Investigator · Awarded by University of Minnesota · 2022 - 2026Open Label Extension study of Rozanolixizumab in CIDP
Clinical TrialPrincipal Investigator · Awarded by UCB Biopharma SPRL · 2020 - 2022A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (ADHERE)
Clinical TrialPrincipal Investigator · Awarded by Argenex BVBA · 2020 - 2022Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Clinical TrialPrincipal Investigator · Awarded by Argenx BVBA · 2021 - 2022Electrical Impedance Myography and Muscle Ultrasound: Longitudinal Measures in Pompe Disease
Clinical TrialInvestigator · Awarded by Genzyme Corporation · 2016 - 2021MultiCenter, Randomized, Double-Blind study of Rozanolixizumab in Subjects with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Clinical TrialPrincipal Investigator · Awarded by UCB Biopharma SPRL · 2020 - 2021Pathogenic Th17 cell pathology in CIDP
ResearchPrincipal Investigator · Awarded by GBS/CIDP Foundation International · 2019 - 2021Mechanisms of Immune Dysregulation in Chronic Inflammatory Demyelinating Polyneuropathy
FellowshipPI-Fellow · Awarded by AANEM Foundation for Research & Education · 2019 - 2020Exploratory Study of BioMarkers Predicting Response to Immunosuppressives in Myasthenia Gravis
Clinical TrialPrincipal Investigator · Awarded by Duke Clinical Research Institute · 2015 - 2020Role of CD4 T Cell subsets as drivers of MG Diseases -EPM 6568
ResearchPrincipal Investigator · Awarded by Myasthenia Gravis Foundation · 2018 - 2019External Relationships
- Accordant Health Services
- Adivo Associates
- Annexon Biosciences, Inc.
- Catalyst Medical Education, LLC
- Clinical Neurological Society of America
- GBS/CIDP Foundation
- Guidepoint
- Immunovant
- In Circle
- Kaplan
- KeyQuest Health
- Magnolia Medical Technologies
- Miller Medical Communication
- North Carolina Neurological Society
- Sanofi
- TECHSPERT
- Takeda Pharmaceutical Co. Ltd.
- University of Pennsylvania
- Wiley Publishing, Inc.
- argenx US, Inc
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.